{
    "clinical_study": {
        "@rank": "52142", 
        "arm_group": [
            {
                "arm_group_label": "CGF166 dose 20 uL", 
                "arm_group_type": "Experimental", 
                "description": "single dose volume #1"
            }, 
            {
                "arm_group_label": "CGF166 dose 40 uL", 
                "arm_group_type": "Experimental", 
                "description": "single dose volume #2"
            }, 
            {
                "arm_group_label": "CGF166 dose 60 uL", 
                "arm_group_type": "Experimental", 
                "description": "single dose volume #3"
            }, 
            {
                "arm_group_label": "CGF166 dose 80 uL", 
                "arm_group_type": "Experimental", 
                "description": "single dose volume #4"
            }, 
            {
                "arm_group_label": "CGF166 dose 90 uL", 
                "arm_group_type": "Experimental", 
                "description": "Single dose volume #5"
            }, 
            {
                "arm_group_label": "CFG166 dose TBD uL", 
                "arm_group_type": "Experimental", 
                "description": "Single dose volume #6"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of the current study is to evaluate the safety, tolerability, and the potential\n      ability of CGF166 delivered through IL-infusion to improve hearing and vestibular function.\n      CGF166 is a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human\n      Atonal transcription factor (Hath1)."
        }, 
        "brief_title": "Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Severe-to-profound Hearing Loss", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe-to-profound Bilateral Hearing Loss With Intact Vestibular Function in the Non-operative Ear.", 
        "condition_browse": {
            "mesh_term": [
                "Hearing Loss", 
                "Deafness", 
                "Hearing Loss, Bilateral"
            ]
        }, 
        "detailed_description": {
            "textblock": "The current study will evaluate the safety, tolerability, and potential efficacy of CGF166\n      and the associated delivery procedures in patients with severe-to-profound bilateral hearing\n      loss. Eligible patients are required to have documented, non-fluctuating hearing loss.  Part\n      A will include a safety and tolerability cohort (N=3).  Patient dosing will be staggered;\n      dosing the next patient in a cohort will be based on a safety review of all available data\n      through 4 weeks post-dose of the previously dosed patient(s). Part B includes a volumetric\n      escalation design to evaluate infusion volumes of the same CGF166 concentration (5.0 x\n      10E11vp/mL) in 4 cohorts of patients (n=3/cohort; total of 12 patients). Part C is an\n      expansion cohort of the highest safe and tolerable dose identified in Part B, for further\n      assessment of efficacy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For all Parts A, B and C of the study,\n\n        Inclusion criteria:\n\n          1. Male or female patients, 21 to 70 years old, inclusive, with severe-to-profound\n             bilateral hearing loss with intact vestibular function in the non-operative ear.\n             Non-fluctuating severe-to-profound hearing loss is required for the study ear and is\n             defined as:\n\n          2. Pure-tone average (PTA) within 10 dB of the PTA obtained at least 11 months\n             previously\n\n          3. Word recognition within 20% of previous test at least 11 months previously\n\n          4. Hearing loss has been diagnosed within 10 years of the expected date of treatment\n\n          5. Candidate ear (\"study ear\") pure tone audiometric thresholds   of \u226570 dB HL for each\n             testable octave frequency from 0.125 through 8 kHz and sentence recognition \u226450% at\n             screening\n\n          6. Contralateral ear (\"non-study ear\"): Despite use of a hearing aid meets cochlear\n             implantation criteria. PTA over  0.5/1/2/4 kHz of \u226570 dB HL and \u2264100 dB HL and\n             sentence recognition test scores \u226460% at screening\n\n          7. Patients with intact vestibular function in at least one ear (non-study ear) as\n             measured by rotary chair vestibular-ocular reflex or caloric nystagmography, or\n             vestibular evoked myogenic potential (VEMP)\n\n          8. MRI scan within 3 months or at screening to confirm suitability for inner ear surgery\n\n          9. Ability to understand the study and provide informed consent; willingness to comply\n             with the protocol\n\n        Exclusion Criteria:\n\n          1. Patients with hearing loss caused by genetic/developmental disorders, e.g., cochlea\n             aplasia or autoimmune ear disease\n\n          2. Patients with existing conductive hearing loss or mixed hearing loss\n\n          3. Patients with cochlear implants or past cochlear implant in the candidate study ear\n\n          4. Hearing loss  due to any other cause that would not be expected to respond to hair\n             cell regeneration, for example mechanical trauma or central auditory lesions or lack\n             of an auditory nerve\n\n          5. Patients who will require ototoxic drugs as routine therapy over the course of the\n             study, such as oncology patients on platinum-based chemotherapy\n\n          6. Any contraindication to the planned surgery or anesthesia as determined by the\n             surgeon or anesthesiologist\n\n          7. Previous surgery in the study ear\n\n          8. Any otological history, such as chronic otitis, cholesteatoma, tympanic membrane\n             perforation, that suggests poor candidacy for cochlear implant or inner ear surgery\n             or suggests potential interference with study auditory or vestibular function tests\n\n          9. Pregnant women\n\n         10. Abnormal vital signs and/or ECG that suggest potential contraindication for planned\n             study anesthesia\n\n         11. Past serious adverse reaction to anesthesia\n\n         12. Meniere's Disease\n\n         13. History of radiation therapy to the head and neck\n\n         14. Participation in a clinical trial within the last 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132130", 
            "org_study_id": "CCGF166X2201"
        }, 
        "intervention": {
            "arm_group_label": [
                "CGF166 dose 20 uL", 
                "CGF166 dose 40 uL", 
                "CGF166 dose 60 uL", 
                "CGF166 dose 80 uL", 
                "CGF166 dose 90 uL", 
                "CFG166 dose TBD uL"
            ], 
            "description": "CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion", 
            "intervention_name": "CGF166", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "gene therapy", 
            "hearing loss", 
            "balance", 
            "vestibular", 
            "cochlear implant"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of patients reported with total adverse events, serious adverse events and death as an assessment of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Sensory thresholds at pure tone frequencies from 0.125 KHz through 16 KHz will be measured using standard audiometric techniques.", 
                "measure": "Change in pure tone audiometry compared to pretreatment values", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132130"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Standard OAE assessments will be performed to evaluate for a clinically significant improvement in signal to noise ratio 6 months following treatment.", 
                "measure": "Change in otoacoustic emission (OAE) testing compared to pretreatment values", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "BAERs will be assessed with standard techniques for clinically significant threshold improvements compared to baseline levels.", 
                "measure": "Change in brainstem auditory evoked responses (BAER) compared to pretreatment values", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Assessments of the vestibular organs for clinically relevant functional improvement", 
                "measure": "effects of CGF166 on various assessments of vestibular function compared to pretreatment values", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Clinically signficant speech recognition improvement (word and/or sentence) following treatment", 
                "measure": "Changes in auditory functions (speech recognition) and vestibular functions before and after IL infusion of CGF166 between the study ear and the contralateral ear", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}